INTRODUCTION {#s1}
============

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease (CHD) with an incidence rate of 1/3600 in live births and 10% in CHD \[[@R1]\]. TOF is characterised by cardiac outflow tract malformation caused by non-uniform separation between truncus arteriosus and bulbus arteriosus during embryo stage. TOF pathological features include ventricular septal defect, aortic overriding, right ventricular outflow tract stenosis or pulmonary artery stenosis and right ventricular hypertrophy. In neonatal period, children with TOF may manifest oxygen deficiency, pneumonia, intractable congestive heart failure and other complications with high early mortality. Despite TOF treatment in children, some complications will still occur because of poor prognosis. TOF brings heavy burden to the family and society. Therefore, to investigate TOF etiology, possible pathogenesis and risk factors for prenatal diagnosis and counselling and prognostic evaluation is of great significance.

Heart development is a complex and orderly process including cardiac tube formation, loop formation, intracardiac separation and vascular connection. Heart development is related to many genes, which express and interact in different spaces and at different times to form a precise regulatory mechanism. Abnormal expression occurring in any of these genes is likely to affect heart development, leading to heart malformation. For TOF, embryonic developmental mechanism is nearly definite. However, the molecular pathogenesis remains to be clarified. TOF is associated with gene mutation \[[@R2]\]. TOF-related genes include *NKX2-5* \[[@R3]\], *GATA4* \[[@R3], [@R4]\], and *JAG-1* \[[@R5], [@R6]\]. Approximately 15% of TOF are from 22q11 microdeletion syndrome \[[@R7]\] caused by chromosome 22 long arm 1 zone 1 subzone deletion and manifest extracardiac abnormalities, such as abnormal face, thymic hypoplasia, cleft palate and hypocalcemia. In addition, TOF is also related to chromosomal aneuploidy, and approximately 3% of TOF is from 21-trisomy syndrome \[[@R8]\]. However, the pathogenesis of isolated TOF is still to be elucidated.

Whole exome sequencing (WES) is suitable to high-throughput sequencing for all genomic exon regions. Human exome accounting for approximately 1%--2% of genome contains important information of protein synthesis, which directly reflects gene function. In most diseases, related mutations are located in the exome region. WES may be used to find pathogenic gene and predisposing gene in complex diseases, monogenic diseases and cancer because it can investigate protein encoding information in several individuals; its data are also accurate \[[@R9]\]. The aim of this study was to find TOF-related pathogenic genes through WES technology performed among eight small families with TOF, providing a basis for studying TOF pathogenesis.

RESULTS {#s2}
=======

Clinical features {#s2_1}
-----------------

All the eight TOF children manifested cyanosis and rough systolic-ejection murmurs at the left sternal border between the second and fourth ribs. Echocardiography showed right ventricular enlargement, right ventricular anterior wall thickening, right ventricular outflow tract and pulmonary artery stenosis, ventricular septal defect and aortic overriding (Figure [1](#F1){ref-type="fig"}). The echocardiographic results of eight TOF children in the right ventricle, right ventricular anterior wall, right ventricular outflow tract, main pulmonary artery, left pulmonary artery, right pulmonary artery, ventricular septal defect and left ventricular ejection fraction (Table [1](#T1){ref-type="table"}). The eight TOF children displayed no other malformations, and their parents showed no abnormalities.

![**(A)** Ventricular septal defect and aortic overriding shown in the left ventricular long-axis view of transthoracic echocardiography. **(B)** Pulmonary artery stenosis shown in the aorta short-axis view of transthoracic echocardiography.\
LA: left atrium; LV: left ventricle; AO: aorta; VSD: ventricular septal defect; RA: right atrium; RV: right ventricle; PA: pulmonary artery; RVOT: right ventricular outflow tract.](oncotarget-08-106976-g001){#F1}

###### Results of echocardiogram in the 8 children with tetralogy of Fallot

  ID   Gender   Age              RV (mm)   RVAW (mm)   RVOT (mm)   MPA (mm)   LPA (mm)   RPA (mm)   VSD (mm)   LVEF (%)
  ---- -------- ---------------- --------- ----------- ----------- ---------- ---------- ---------- ---------- ----------
  1    female   3months          8.0       5.0         5.4         5.6        4.3        4.8        9.5        73
  2    male     8months27days    12.0      6.0         5.7         5.3        4.3        5.3        10.2       68
  3    male     1years11months   13.9      6.8         7.2         10.5       6.6        6.7        13.5       72
  4    female   2months24days    11.8      4.1         6.0         15.3       9.3        7.7        11.5       57
  5    female   6months          11.1      6.1         9.0         11.8       7.6        7.6        12.9       67
  6    male     8months2days     13.0      6.3         7.0         6.4        4.2        4.4        13.5       72
  7    female   11months26days   13.4      5.9         5.8         12.4       6.7        7.1        13.1       69
  8    male     6months11days    10.3      5.0         6.1         9.0        4.3        5.7        13.2       74

RV: right ventricle; RVAW: right ventricular anterior wall; RVOT: Right ventricular outflow tract; MPA: main pulmonary artery; LPA: left pulmonary artery; RPA: right pulmonary artery; VSD: ventricular septal defect; LVEF: left ventricular ejection fraction.

Mutation detection {#s2_2}
------------------

A total of sixteen differential single nucleotide polymorphisms (SNPs) loci and eight differentially small InDels were discovered by sequencing all exons in the eight small families and alignment of SNPs and small InDels within families and between families (Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}).

###### SNPs identified by whole exome sequencing

  Chr     Position    ID            Ref   Alt   Mutation      Symbol       Amino acids   SIFT               PolyPhen
  ------- ----------- ------------- ----- ----- ------------- ------------ ------------- ------------------ -----------------
  chr12   56717682    rs745387506   T     G     missense      *NACA*       H/P           \-                 unknown(0)
  chr5    141123595   \-            T     A     missense      *PCDHB4*     S/T           tolerated (1)      benign(0)
  chr12   7190555     \-            G     C     missense      *PEX5*       A/P           tolerated (0.22)   benign(0.067)
  chr2    240042663   \-            C     T     missense      *PRR21*      R/H           tolerated (0.56)   unknown(0)
  chr4    1237208     \-            A     T     stop_gained   *CTBP1*      C/\*          \-                 \-
  chrX    37010556    rs61999275    G     C     missense      *FAM47C*     A/P           tolerated(1)       benign(0)
  chr1    26282352    rs6667693     C     A     missense      *UBXN11*     G/C           tolerated (0.05)   unknown(0)
  chr1    86368686    rs75376884    T     C     missense      *ODF2L*      M/V           tolerated (0.14)   benign(0.001)
  chr4    87614868    \-            G     A     missense      *DSPP*       D/N           \-                 unknown(0)
  chr4    87614877    rs150132251   A     G     missense      *DSPP*       N/D           \-                 unknown(0)
  chr4    88008301    rs117078377   G     A     missense      *PKD2*       A/T           tolerated(0.3)     benign(0.395)
  chr11   71527593    rs199903176   A     G     missense      *KRTAP5-7*   Y/C           tolerated (0.22)   unknown(0)
  chr12   51346625    rs117443541   T     G     missense      *CELA1*      Y/S           tolerated(0.13)    benign(0.045)
  chr15   88856792    rs12899191    A     G     missense      *ACAN*       T/A           tolerated(0.56)    benign(0.084)
  chrX    104250509   rs9697856     T     G     missense      *ESX1*       T/P           tolerated (0.54)   unknown(0)
  chr22   11068057    \-            A     T     missense      *BAGE5*      R/W           tolerated (0.12)   damaging(0.675)

Chr: chromosome; Ref: reference sequence base; Alt: alternative base identified; SIFT: sorting intolerant from tolerant.

###### Small InDels identified by whole exome sequencing

  Chr     Position    ID            Ref        Alt      Mutation                                                Symbol      Amino acids   SIFT   PolyPhen
  ------- ----------- ------------- ---------- -------- ------------------------------------------------------- ----------- ------------- ------ ----------
  chr2    104856098   rs775150602   AGCC       A        inframe_deletion                                        *POU3F3*    A/-           \-     \-
  chr12   111598972   rs769170503   C          CTGT     inframe_insertion                                       *ATXN2*     Q/QQ          \-     \-
  chr4    13632182    .             CT         C        splice_acceptor_variant&non_coding_transcript_variant   *-*         \-                   
  chr9    136327352   .             ACCCCCTC   A        TF_binding_site_variant&TFBS_ablation                   *GPSM1*     \-            \-     \-
  chr17   75616380    rs371699907   CAGG       C        inframe_deletion                                        *MYO15B*    QE/Q          \-     \-
  chr19   9251064     rs201985790   CT         C        frameshift_variant                                      *OR7E24*    F/X           \-     \-
  chr19   51694076    rs10689461    C          CAG      splice_acceptor_variant&non_coding_transcript_variant   *SPACA6P*   \-            \-     \-
  chrX    19345745    rs776856509   TC         TCC, T   frameshift_variant                                      *PDHA1*     S/X           \-     \-

Ten of the sixteen differential SNPs were reported, namely, Chr1 (rs6667693, *UBXN11*), Chr1 (rs75376884, *ODF2L*), Chr4 (rs150132251, *DSPP*), Chr4 (rs117078377, *PKD2*), Chr11 (rs199903176, *KRTAP5-7*), Chr12 (rs745387506, *NACA*), Chr12 (rs117443541, *CELA1*), Chr15 (rs12899191, *ACAN*), ChrX (rs61999275, *FAM47C*) and ChrX rs9697856, *ESX1*). Six of the 16 differential SNPs were not reported, namely, Chr 2 (*PRR21*), Chr 4 (*CTBP1*), Chr 4 (*DSPP*), Chr 5 (*PCDHB4*), Chr12 (*PEX5*) and Chr22 (*BAGE5*).

Six of the eight differentially small InDels were reported, namely, Chr2 (rs775150602, *POU3F3*), Chr12 (rs769170503, *ATXN2*), Chr17 (rs371699907, *MYO15B*), Chr19 (rs201985790, *OR7E24*), Chr19 (rs10689461, *SPACA6P*) and ChrX (rs776856509, *PDHA1*). Two of the eight differentially small InDels were not reported, namely, Chr4 (position: 13632182) and Chr9 (*GPSM1*).

SNPs and small InDel-related Online Mendelian Inheritance in Man (OMIM) genes and clinical phenotypes are shown in Table [4](#T4){ref-type="table"}.

###### SNPs- and small InDels-related OMIM genes and clinical phenotypes

  Gene         Chromosome   OMIM     Gene description                                                                                                                                                                                                     Function
  ------------ ------------ -------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *NACA*       Chr12        601234   gene encodes a protein that associates with *BTF3* to form *NAC*                                                                                                                                                     skeletal development
  *PCDHB4*     Chr5         606330   a member of the protocadherin beta gene cluster                                                                                                                                                                      cell-cell neural connections
  *PEX5*       Chr12        600414   peroxisomal biogenesis factor 5                                                                                                                                                                                      Peroxisome biogenesis disorder 2A, 2B; Rhizomelic chondrodysplasia punctata, type 5
  *PRR21*      Chr2         \-       \-                                                                                                                                                                                                                   \-
  *CTBP1*      Chr4         602618   gene encodes a protein that binds to the C-terminus of adenovirus E1A proteins                                                                                                                                       transcriptional repressor and cellular proliferation
  *FAM47C*     ChrX         \-       \-                                                                                                                                                                                                                   \-
  *UBXN11*     Chr1         609151   a protein with a divergent C-terminal UBX domain                                                                                                                                                                     affect the actin cytoskeleton and alter cell shape
  *ODF2L*      Chr1         \-       \-                                                                                                                                                                                                                   \-
  *DSPP*       Chr4         125485   a member of the small integrin-binding ligand N-linked glycoprotein family of proteins                                                                                                                               Deafness, autosomal dominant 39, with dentinogenesis; Dentin dysplasia, type II; Dentinogenesis imperfecta, Shields type II, III
  *PKD2*       Chr4         173910   a member of the polycystin protein family                                                                                                                                                                            Polycystic kidney disease 2
  *KRTAP5-7*   Chr11        \-       \-                                                                                                                                                                                                                   \-
  *CELA1*      Chr12        130120   Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin                                                                                                                   evolutionarily silenced in pancreatic acinar cells
  *ACAN*       Chr15        155760   a member of the aggrecan/versican proteoglycan family                                                                                                                                                                Osteochondritis dissecans, short stature, and early-onset osteoarthritis; Spondyloepimetaphyseal dysplasia, aggrecan type; Spondyloepiphyseal dysplasia, Kimberley type
  *ESX1*       ChrX         300154   gene encodes a dual-function 65 kDa protein that undergoes proteolytic cleavage to produce a 45 kDa N-terminal fragment with a paired-like homeodomain and a 20 kDa C-terminal fragment with a proline-rich domain   placental development and spermatogenesis
  *BAGE5*      Chr22        \-       \-                                                                                                                                                                                                                   \-
  *POU3F3*     Chr2         602480   a member of the class III *POU* family of transcription factors                                                                                                                                                      expressed in the central nervous system
  *ATXN2*      Chr12        601517   gene belongs to a group of genes that is associated with microsatellite-expansion diseases, a class of neurological and neuromuscular disorders caused by expansion of short stretches of repetitive DNA             Spinocerebellar ataxia 2; susceptibility to Amyotrophic lateral sclerosis; susceptibility to Parkinson disease, late-onset
  *GPSM1*      Chr9         609491   gene encodes a receptor-independent activator of G protein signaling,                                                                                                                                                influence the basal activity of G-protein signaling systems
  *MYO15B*     Chr17        \-       \-                                                                                                                                                                                                                   \-
  *OR7E24*     Chr19        \-       \-                                                                                                                                                                                                                   \-
  *SPACA6P*    Chr19        \-       \-                                                                                                                                                                                                                   \-
  *PDHA1*      ChrX         300502   a nuclear-encoded mitochondrial multienzyme complex that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and provides the primary link between glycolysis and the tricarboxylic acid cycle     Pyruvate dehydrogenase E1-alpha deficiency

We discovered fourteen SNPs- and Small InDels-related OMIM genes, including: *NACA*, *PCDHB4*, *PEX5*, *CTBP1*, *UBXN11*, *DSPP*, *PKD2*, *CELA1*, *ACAN*, *ESX1*, *POU3F3*, *ATXN2*, *GPSM1*, *PDHA1. PEX5* (OMIM:600414) is associated with Peroxisome biogenesis disorder 2A, 2B. *NACA* (OMIM:601234) is associated with skeletal development. *ATXN2* (OMIM:601517) is associated with Spinocerebellar ataxia 2, susceptibility to Amyotrophic lateral sclerosis, susceptibility to Parkinson disease and late-onset. *CELA1* (OMIM:130120) is associated with evolutionarily silenced in pancreatic acinar cells. *PCDHB4* (OMIM:606330) cell-cell neural connections is associated with *CTBP1*(OMIM:602618) transcriptional repressor and cellular proliferation.

Results verified by Sanger sequencing {#s2_3}
-------------------------------------

We designed twenty-four pairs of primers to verify sixteen differential SNPs loci and eight differentially small InDels. The results of Sanger sequencing are consistent with that of WES (Figure [2](#F2){ref-type="fig"}).

![Diagram of the Sanger sequencing for two mutations\
**(A)** chr4:13632182 (CT→C). **(B)** chr1:86368686 (T→C).](oncotarget-08-106976-g002){#F2}

The verification of sixteen differential SNPs sites included *NACA* (rs745387506, T\>G), *FAM47C* (rs61999275, G\>C), *UBXN11* (rs6667693, C\>A), *ODF2L* (rs75376884, T\>C), *DSPP* (rs150132251, A\>G), *PKD2* (rs117078377, G\>A), *KRTAP5-7* (rs199903176, A\>G), *CELA1* (rs117443541, T\>G), *ACAN* (rs12899191, A\>G), *ESX1* (rs9697856, T\>G), *PCDHB4* (chr5, 141123595, T\>G), *PEX5* (chr12, 7190555, G\>C), *PRR21* (chr2, 240042663, C\>T), *CTBP1* (chr4, 1237208, A\>T), *DSPP* (chr4, 87614868, G\>A) and *BAGE5* (chr22, 11068057, A\>T) were investigated.

The verification of eight differentially small InDels sites included *AGCC* (rs775150602, AGCC\>A), *ATXN2* (rs769170503, C\>CTGT), *MYO15B* (rs371699907, CAGG\>C), *OR7E24* (rs201985790, CT\>C), *SPACA6P* (rs10689461, C\>CAG), *PDHA1* (rs776856509, TC\>TCCT), *GPSM1* (chr9, 136327352, ACCCCCTC\>A), and (chr4, 13632182, CT\>T) were investigated.

Gene ontology (GO)/pathway analysis {#s2_4}
-----------------------------------

GO analysis indicated the percentages of 22 genes enriched in GO term (Figure [3](#F3){ref-type="fig"}). Growth was related to CHD, and it was associated with some genes including *PEX5*, *NACA*, *ATXN2* and *CELA1* (Table [5](#T5){ref-type="table"}). *PEX5*, *ATXN2* and *CELA1* are responsible for multicellular organism growth (GO:0035264). *PEX5*, *ATXN2*, *NACA* and *CELA1* are responsible for developmental growth (GO:0048589). *PEX5*, *ATXN2* and *NACA* are responsible for regulation of developmental growth (GO:0048638) and growth regulation (GO:0040008). *PEX5* and *ATXN2* are responsible for regulation of multicellular organism growth (GO:0040014). *PEX5* and *NACA* are responsible for positive regulation of developmental growth (GO:0048639) and positive growth regulation (GO:0045927). *PEX5* is responsible for positive regulation of multicellular organism growth (GO:0040018). *ATXN2* is responsible for negative regulation of multicellular organism growth (GO:0040015), epidermal growth-factor receptor binding (GO:0005154), negative regulation of developmental growth (GO:0048640), growth-factor receptor binding (GO:0070851) and negative growth regulation (GO:0045926).

![GO analysis of 22 genes](oncotarget-08-106976-g003){#F3}

###### Genes involved by growth and possibly associated with CHD in GO term

  Gene                                                   Term                                                   Database             ID
  ------------------------------------------------------ ------------------------------------------------------ -------------------- ------------
  *PEX5*:5830\|*ATXN2*:6311\|*CELA1*:1990                multicellular organism growth                          Biological Process   GO:0035264
  *PEX5*:5830\|*ATXN2*:6311\|*NACA*:4666\|*CELA1*:1990   developmental growth                                   Biological Process   GO:0048589
  *PEX5*:5830\|*ATXN2*:6311\|*NACA*:4666                 regulation of developmental growth                     Biological Process   GO:0048638
  *PEX5*:5830\|*ATXN2*:6311                              regulation of multicellular organism growth            Biological Process   GO:0040014
  *PEX5*:5830\|*NACA*:4666                               positive regulation of developmental growth            Biological Process   GO:0048639
  *PEX5*:5830\|*ATXN2*:6311\|*NACA*:4666\|*CELA1*:1990   growth                                                 Biological Process   GO:0040007
  *PEX5*:5830\|*NACA*:4666                               positive regulation of growth                          Biological Process   GO:0045927
  *PEX5*:5830\|*ATXN2*:6311\|*NACA*:4666                 regulation of growth                                   Biological Process   GO:0040008
  *PEX5*:5830                                            positive regulation of multicellular organism growth   Biological Process   GO:0040018
  *ATXN2*:6311                                           negative regulation of multicellular organism growth   Biological Process   GO:0040015
  *ATXN2*:6311                                           epidermal growth factor receptor binding               Molecular Function   GO:0005154
  *ATXN2*:6311                                           negative regulation of developmental growth            Biological Process   GO:0048640
  *ATXN2*:6311                                           growth factor receptor binding                         Molecular Function   GO:0070851
  *ATXN2*:6311                                           negative regulation of growth                          Biological Process   GO:0045926

Repression of Wnt target genes and Notch signalling were related to CHD, and was associated with *PCDHB4* and *CTBP1* genes (Table [6](#T6){ref-type="table"}). Pathway analysis showed that twenty-two genes were enriched at the top fifty of pathway term (Figure [4](#F4){ref-type="fig"}). Genes involved in the Wnt (*CTBP1* and *PCDHB4*) and Notch (*CTBP1*) signalling are important for pathway analysis in cardiac development. The mutation sites in the six genes were as follows: *PEX5* (A60P), *NACA* (H1283P), *ATXN2* (Q21QQ), *CELA1* (Y5S), *PCDHB4* (S533T) and *CTBP1* (C35^\*^). The transcript number of *ATXN2* (Q21QQ) is ENST00000608853.5, and the transcript number of CTBP1 (C35^\*^) is ENST00000629223.1.

###### Genes involved by pathway and possibly associated with CHD

  Gene                           Term                                                                                         Database       ID
  ------------------------------ -------------------------------------------------------------------------------------------- -------------- --------------
  *CTBP1*:1487                   repression of WNT target genes                                                               Reactome       REACT_264567
  *CTBP1*:1487                   *AXIN* mutants destabilize the destruction complex, activating WNT signaling                 Reactome       REACT_264496
  *CTBP1*:1487                   deletions in the *AXIN* genes in hepatocellular carcinoma result in elevated WNT signaling   Reactome       REACT_264286
  *CTBP1*:1487                   WNT signaling pathway                                                                        KEGG PATHWAY   hsa04310
  *CTBP1*:1487                   *TCF* dependent signaling in response to WNT                                                 Reactome       REACT_264596
  *CTBP1*:1487                   *RNF* mutants show enhanced WNT signaling and proliferation                                  Reactome       REACT_264378
  *CTBP1*:1487                   Signaling by WNT                                                                             Reactome       REACT_11045
  *CTBP1*:1487                   Notch signaling pathway                                                                      KEGG PATHWAY   hsa04330
  *PCDHB4*:56131\|*CTBP1*:1487   WNT signaling pathway                                                                        PANTHER        P00057

![Pathway analysis of 22 genes](oncotarget-08-106976-g004){#F4}

Variant analysis {#s2_5}
----------------

By alignment of protein sequences of *PEX5*, *NACA*, *ATXN2*, *CELA1*, *PCDHB4* and *CTBP1*, S5333T of *PCDHB4* was highly evolutionarily conserved in diverse species including *Homo sapiens*, *Pan paniscus*, *Pongo abelii* and gorilla (Figure [5a](#F5){ref-type="fig"}). In addition, Y5S of *CELA1* was highly evolutionarily conserved in diverse species including *H. sapiens*, gorilla, Saimiri *boliviensis*, *Papio anubis*, *Peromyscus maniculatus*, *Tapirus bairdii*, *Eptesicus fuscus* and *Sus scrofa* (Figure [5b](#F5){ref-type="fig"}). The highly evolutionarily conserved protein sequences were not found in *PEX5*, *NACA*, *ATXN2* and *CTBP1* in other species.

![**(A)** Alignment of multiple *PCDHB4* protein sequences in different species reveals that the S533T amino acid is located in the highly conserved amino acid region in different species. **(B)** Alignment of multiple *CELA1* protein sequences in different species reveals that the Y33T amino acid is located in the highly conserved amino acid region in different species.](oncotarget-08-106976-g005){#F5}

DISCUSSION {#s3}
==========

TOF as the most common cyanotic CHD is characterised by right ventricular outflow tract obstruction, pulmonary stenosis, ventricular septal defect and aortic overriding caused by non-uniform separation between the truncus arteriosus and bulbus arteriosus at embryo stage. Currently, surgical repair is usually performed in the first month after birth to relieve the stenosis of the right outflow tract and close ventricular septal defect, enabling an exclusive ejection of oxygenated blood via the left ventricle. Cumulative survival and event-free survival were 72% and 25%, respectively, 40 years after follow-up \[[@R12]\].

TOF etiology still needs to be completely clarified because of TOF complexity attributed by both genetic and nongenetic effectors. Next-generation sequencing technology, such as WES with rapid, high throughput and cost-effective features, can meet the requirements for medical studies. WES has been used to obtain information about genetic alterations and potential predispositions possibly associated with TOF occurrence.

Eight small families were tested through WES, and differential SNP loci and InDels were found. From the comparison within each family and among the families, sixteen differential SNPs loci and eight differential Small InDels were screened out. Corresponding genes exist in the database, wherein ten of the sixteen differential SNPs have been reported and six of the sixteen differential SNPs have not been reported. Among the eight Small InDels, seven small Indels have corresponding genes in the database and one Small InDels does not have. Six of the eight differential Small InDels have been reported, whereas two of them have not. Among them, no gene in the database corresponds to the mutation of chr4, position: 13632182. It might be located among the genes or among noncoding regions, and the function requires further study. Go/Pathway analysis of the sixteen differential SNPs loci and eight differential Small InDels were conducted and *PEX5*, *NACA*, *ATXN2*, *CELA1*, *PCDHB4* and *CTBP1* were finally screened out and were associated with TOF.

Similar to some genes found to be related to TOF by detection of chromosome karyotype, gene copy number variation and de novo mutation (Table [7](#T7){ref-type="table"}), Greenway et al. \[[@R13]\] found four genes (*PRKAB2*, *CHD1L*, *BCL9* and *GJA5*) with the highest expression in the right ventricular outflow tract, which is malformed in TOF. Bittel et al. \[[@R14]\] included both idiopathic TOF patients and three patients, which harbour the syndromic 22q11.2 deletion. The expression of the genes *A2BP1*, *VEGF*, *NPPA* and *NPPB* located in the 22q11.2 region was half-reduced among syndromic patients as expected, whereas none of these genes was differentially expressed in any of the idiopathic TOF subjects. Notch pathway was also suppressed in patients with 22q11.2 deletions. Sharma et al. \[[@R15], [@R16]\] found that TOF expression of the majority of the genes associated with Wnt and Notch signalling pathways was significantly reduced. Their results also confirmed an upregulated expression of *VEGF* and proteins of the extracellular matrix reported in previous studies. Feiner et al. \[[@R17]\] found a novel locus at 1q32.2 in two unrelated TOF who displayed loss of copy number variations overlapping the *PLXNA2* gene. Knockout mice deficient for *PLXNA2* display CHD including TOF \[[@R18]\]. Amarillo et al. \[[@R19]\] found a 3.76 Mb de novo contiguous gain of 9q34.2-q34.3 by chromosome microarray analysis and then also confirmed it by karyotype analysis and fluorescence *in situ* hybridization. This duplicated interval disrupted retinoid X receptor alpha (OMIM ^\#^180245) at intron 1. To our knowledge, *PEX5*, *PCDHB4*, *CTBP1*, *NACA*, *ATXN2* and *CELA1* are novel SNPs associated with TOF, which have not been reported.

###### Summary of genes with a potential relevance to TOF

  References                       Subjects                Platform                                                                              Genes                                                                                                                               Conclusions
  -------------------------------- ----------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Steven C et al (2009)            114 TOF Trios 398 TOF   Affymetrix Human Genome Wide SNP Array 6.0                                            *PRKAB2, CHDIL, BCL9, GJA5*                                                                                                         potential TOF candidate gene
  Douglas C Bittel et al (2011)    19 TOF                  Applied Microarrays Inc. CodeLink Human Whole Genome Bioarray                         *A2BP1, VEGF, NPPA, NPPB*,                                                                                                          potential relevance for TOF
  Amy Rodemoyer et al (2011)       16 TOF                  Affymetrix Human Exon 1.0 ST v2                                                       *NEFH, SST, TF, KRT6A, KRT7, NTRK2, MYL2, PPBP, NRGN*, *APOC3*                                                                      dysregulated network in TOF
  Goodship et al (2012)            362 TOF                 SEQUENOM MALDI-TOF                                                                    *PTPN11*                                                                                                                            risk allele for TOF
  Candice K et al (2012)           433 TOF                 Affymetrix Genome-Wide Human SNP Array 6.0                                            *GJA5, PLXNA2*                                                                                                                      potential TOF candidate gene
  Rachel Soemedi et al (2012)      283 TOF Trios           Illumina 660W SNP Array 6.0                                                           *GJA5, HAND2, EDIL3, CNOT6*                                                                                                         potential TOF candidate gene
  Heather J.Cordell et al (2013)   798 TOF                 Illumina 600W QUAD array                                                              *PTPN11, GPC5, NRP1*                                                                                                                risk allele for TOF
  Marcel Grunert et al (2014)      22 TOF                  NimbleGen sequence capture 365K array Genome Sequencer FLX Illumina Genome Analyzer   deleterious SNPs in *BARX1, BCCIP, DAG1, EDN1, FANCL, FANCM, FMR1, FOXK1, HCN2, MYOM2, PEX6, ROCK1, TCEB3, TP53BP2, TTN, WBSCR16*   imbalance of functional networks in TOF
  Tan ZP et al (2015)              1 TOF                   Illumina Hiseq2000                                                                    *SCN5A*                                                                                                                             a possible cause of TOF
  LaHaye S et al (2016)            2 TOF                   Illumina Hiseq2000                                                                    *MYBPC3, SOS1*                                                                                                                      uncertain significance

Our study aimed to identify other monogenic causes of TOF. GO analysis indicated that *PEX5* was related to multicellular organism growth (GO:0035264), developmental growth (GO:0048589), regulation of developmental growth (GO:0048638), regulation of multicellular organism growth (GO:0040014), positive regulation of developmental growth (GO:0048639), positive regulation of growth (GO:0045927), growth (GO:0040007) and positive regulation of multicellular organism growth. In the 26 cases with TOF, Grunert M et al. \[[@R20]\] found deleterious SNPs in 16 genes, including *BARX1*, *BCCIP, DAG1*, *EDN1*, *FANCL*, *FANCM*, *FMR1*, *FOXK1*, *HCN2*, *MYOM2*, *PEX6*, *ROCK1*, *TCEB3*, *TP53BP2*, *TTN* and *WBSCR16* which resulted in the imbalance of function networks in TOF. Huffnagel IC et al.\[[@R21]\] found that two of the 21 genetically proven Rhizomelic chondrodysplasia punctata patients suffered from TOF and showed *PEX7* mutations. Plasmalogens were not detected in cardiac tissue of *PEX7* knock-out mice, which is a model for RCDP type 1. The above-mentioned *PEX5, PEX6* and *PEX7* are all *PEX* family gene named Peroxins (PEXs) which are proteins essential for the assembly of functional peroxisomes. Therefore, *PEX5* might participate in TOF growth and development process. *PCDHB4* is located on Chr5q31.3. This gene is a member of the protocadherin beta gene cluster and is one of the three related and tandemly linked gene clusters at chromosome 5. Their specific functions are unknown but they most likely play a critical role in the establishment and function of specific cell--cell neural connections. Alazami AM et al. \[[@R22]\] performed WES on 143 multiplex consanguineous families, in which known disease genes had been excluded by autozygosity mapping. Patients, whose clinical phenotype is featured by global developmental delay and brain atrophy, have mutation in *PCDHB4* (NM_021908:c.489T\>G:p.Y163X) based on the candidate gene analysis, and the function of which participated in the growth and development process. Base on our research, Go analysis indicated that *PCDHB4* (P00057) was related to WNT signaling pathway. Thus, *PCDHB4* (P00057) may be a potential TOF candidate gene. *NACA* is located on Chr12q13.3. The protein encoded by *NACA* is associated with basic transcription factor 3, which forms the nascent polypeptide-associated complex. In this study, GO analysis indicated that *NACA* was related to positive regulation of developmental growth (GO:0048639) and positive regulation of growth (GO:0045927). Thus, *NACA* may be a potential TOF candidate gene. *CELA1* is located on Chr12q13.13. This gene forms a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Humans possess six elastase genes, which encode the structurally similar elastases 1, 2, 2A, 2B, 3A and 3B. Unlike other elastases, pancreatic elastase 1 is not expressed in the pancreas. GO analysis indicated that *CELA1* was related to multicellular organism growth (GO:0035264), developmental growth (GO:0048589) and growth (GO:0040007). Thus, *CELA1* may have a potential relevance to TOF. *ATXN2* is located on Chr12q24.12 with a transcript number of ENST00000608853.5. This gene belongs to a group of genes that are associated with microsatellite-expansion diseases, a class of neurological and neuromuscular disorders caused by expansion of short stretches of repetitive deoxyribonucleic acid (DNA). Genome-wide association studies indicate that loss-of-function mutations in this gene may be associated with susceptibility to type I diabetes, obesity and hypertension. Alternative splicing leads to multiple transcript variants. GO analysis indicated that *ATXN2* was related to negative regulation of multicellular organism growth (GO:0040015), epidermal growth-factor receptor binding (GO:005154), negative regulation of developmental growth (GO:0048640), growth-factor receptor binding (GO:0070851) and negative regulation of growth (GO:0045926). Thus, *ATXN2* may have a potential relevance to TOF. *CTBP1* is located on Chr4p16.12 with a transcript number of ENST00000629223.1. This gene encodes a protein that binds to the C-terminus of adenovirus E1A proteins. This phosphoprotein is a transcriptional repressor and may play a role in cellular proliferation. This protein and the product of a second closely related gene, *CTBP1*, can dimerise. Both proteins can also interact with a polycomb group protein complex, which participates in regulation of gene expression during development. Alternative splicing of transcripts from this gene results in multiple transcript variants. GO analysis indicated that *CTBP1* was related to Wnt signalling pathway and Notch signalling pathway. Thus, *CTBP1* may be a potential TOF candidate gene.

This study has some limitations, and the sample size is small. In the future, the number of samples will be further increased and an in-depth research will be conducted. The identified mutation sites have not been verified based on large TOF sample (n\>50). Thus, whether the identified mutation sites may occur in a large group of TOF people has not been confirmed. Moreover, further study is necessary to verify relevant function genes and accordingly illustrate the pathogenesis of TOF.

In summary, TOF pathogenesis is complex because TOF is associated with more than one genetic variant. Eight small families were observed through WES and found that TOF-related genes were *PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1*, whose potential function might participate in TOF growth and development process. Although none of the three variants were predicted to be highly influential, they are in genes belonging to networks involved in relevant developmental pathways. Further study on the potential developmental mechanisms will be conducted based on these results.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total of eight small families whose Chinese children received surgical TOF treatment at the Children's Heart Center of Henan Provincial People's Hospital between January 2016 and June 2016 were enrolled in this study. The eight children ageing 3--11 months included four male babies and four female babies. All manifested isolated TOF. Their parents were normal. All the eight children were diagnosed with TOF by echocardiogram, clinical symptoms and signs and intraoperative findings.

Methods {#s4_2}
-------

### DNA extraction {#s4_2_1}

In each member of the eight small families including 24 individuals, 600 μl peripheral blood was collected to extract genomic DNA using genomic DNA Extraction Kit (Qiage, Germany). The remaining blood samples were stored at −80°C.

### WES and mutation screening {#s4_2_2}

WES and subsequent variant annotation were performed on genomic DNA derived from the eight TOF children and their parents. Paired-end libraries were prepared according to the manufacturer's protocols (Agilent). Exome libraries for the eight families were constructed using Agilent SureSelectXT Target Enrichment System according to Illumina Paired End Sequencing Protocol (Agilent Technologies, CA, USA). Capturing of whole exon was carried out according to the protocol of Agilent's Sure Select Human All 1 UTRs 71 MB v4 kit. The flow cells were sequenced as paired-end 150 base pair reads on an Illumina HiSeq ×10 platform to a minimum depth of 50× targeted region coverage using TruSeq SBS sequencing kit version 3 and HiSeq data collection version 2.0.12.0 software (Illumina, Inc., San Diego, CA, USA).

The raw sequence reads we obtained were aligned to the human genome reference sequence (hg19) using Burrows--Wheeler Aligner (BWA) with standard parameters \[[@R10]\]. The BWA-aligned reads were statistically calculated using PICARD software to exclude polymerase chain reaction duplicates. Regional realignment and quality score recalibration were carried out using Genome Analysis Toolkit \[[@R11]\] with recommended parameters, which included local realignment of the sequences around InDels, base quality score recalibration, variant calling and variant quality score recalibration.

### Variant detection in the eight TOF children by Sanger sequencing {#s4_2_3}

BigDye^®^ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and ABI 3130 Genetic Analyzer were used to detect variants among the eight TOF children.

Ethics statement {#s4_3}
----------------
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TOF

:   tetralogy of Fallot

CHD

:   congenital heart disease

WES

:   whole-exome sequencing

SNPs

:   single nucleotide polymorphisms

CNVs

:   copy number variations

DNA

:   deoxyribonucleic acid

BWA

:   Burrows--Wheeler Aligner

GATK

:   Genome Analysis Toolkit

BTF3

:   basic transcription factor 3

NAC

:   nascent polypeptide-associated complex

SRP

:   signal recognition particle
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